Analysts forecast that United Therapeutics Co. (NASDAQ:UTHR) will announce sales of $384.73 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for United Therapeutics’ earnings, with estimates ranging from $350.20 million to $418.75 million. United Therapeutics reported sales of $370.50 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 3.8%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, April 25th.
According to Zacks, analysts expect that United Therapeutics will report full-year sales of $1.44 billion for the current fiscal year, with estimates ranging from $1.35 billion to $1.57 billion. For the next financial year, analysts forecast that the company will report sales of $1.28 billion per share, with estimates ranging from $1.21 billion to $1.37 billion. Zacks’ sales averages are a mean average based on a survey of research firms that follow United Therapeutics.
United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $3.89 earnings per share for the quarter, beating analysts’ consensus estimates of $3.59 by $0.30. The company had revenue of $464.70 million for the quarter, compared to the consensus estimate of $420.55 million. United Therapeutics had a return on equity of 24.41% and a net margin of 24.22%. The company’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the business earned $4.12 earnings per share.
In related news, CEO Martine A. Rothblatt sold 43,025 shares of the business’s stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $111.11, for a total value of $4,780,507.75. Following the completion of the transaction, the chief executive officer now owns 21,652 shares in the company, valued at approximately $2,405,753.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 301 shares of the business’s stock in a transaction that occurred on Tuesday, March 20th. The stock was sold at an average price of $110.48, for a total transaction of $33,254.48. Following the completion of the transaction, the chief executive officer now owns 21,652 shares of the company’s stock, valued at approximately $2,392,112.96. The disclosure for this sale can be found here. Insiders sold a total of 174,046 shares of company stock valued at $19,506,251 in the last 90 days. 7.80% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of UTHR. Legal & General Group Plc raised its position in United Therapeutics by 10.5% in the 3rd quarter. Legal & General Group Plc now owns 89,846 shares of the biotechnology company’s stock worth $10,530,000 after purchasing an additional 8,549 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp raised its position in United Therapeutics by 1.3% in the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 88,399 shares of the biotechnology company’s stock worth $10,359,000 after purchasing an additional 1,124 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in United Therapeutics by 4.4% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 150,028 shares of the biotechnology company’s stock worth $17,582,000 after purchasing an additional 6,304 shares during the last quarter. Dimensional Fund Advisors LP raised its position in United Therapeutics by 9.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 798,093 shares of the biotechnology company’s stock worth $93,531,000 after purchasing an additional 71,333 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its position in United Therapeutics by 496.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 8,511 shares of the biotechnology company’s stock worth $997,000 after purchasing an additional 7,085 shares during the last quarter.
Shares of UTHR traded up $1.21 on Tuesday, hitting $114.09. The company’s stock had a trading volume of 326,656 shares, compared to its average volume of 438,790. The company has a market capitalization of $4,863.17, a P/E ratio of 10.48 and a beta of 1.33. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.26 and a quick ratio of 3.01. United Therapeutics has a fifty-two week low of $106.30 and a fifty-two week high of $152.55.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.